Alvotech Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Robert Wessman

Amministratore delegato

US$1.5m

Compenso totale

Percentuale dello stipendio del CEO	98.3%
Mandato del CEO	1.8yrs
Proprietà del CEO	n/a
Durata media del management	1.8yrs
Durata media del Consiglio di amministrazione	3.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Robert Wessman rispetto agli utili di Alvotech?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	-US$618m
Mar 31 2024	n/a	n/a	-US$494m
Dec 31 2023	US$2m	US$1m	-US$552m
Sep 30 2023	n/a	n/a	-US$596m
Jun 30 2023	n/a	n/a	-US$416m
Mar 31 2023	n/a	n/a	-US$713m
Dec 31 2022	US$740k	n/a	-US$514m

Compensazione vs Mercato: La retribuzione totale di Robert ($USD 1.52M ) è circa la media per le aziende di dimensioni simili nel mercato IS ($USD 1.87M ).

Compensazione vs guadagni: La retribuzione di Robert è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Robert Wessman (54 yo)

1.8yrs

Mandato

US$1,517,000

Compensazione

Mr. Robert Wessman serves as Chief Executive Officer of Alvotech since January 1, 2023. He Founded Alvotech in 2013 and serves as its Executive Chairman and Member of the Board of Directors since January 2...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Robert Wessman	CEO, Founder & Executive Chairman	1.8yrs	US$1.52m	Nessun dato
Faysal Kalmoua	COO & Director	1.1yrs	Nessun dato	0% ISK 0
Joel Morales	Chief Financial Officer	4.7yrs	Nessun dato	0.032% ISK 172.2m
Giedrius Zunda	Chief Technical Officer	no data	Nessun dato	Nessun dato
Joseph McClellan	Chief Scientific Officer	5yrs	Nessun dato	0.051% ISK 273.5m
Tanya Zharov	General Counsel	1.8yrs	Nessun dato	0% ISK 0
Jenny Steingrimsdottir	Vice President of People & Culture	less than a year	Nessun dato	Nessun dato
Anil Okay	Chief Commercial Officer	6.3yrs	Nessun dato	Nessun dato
Ming Li	Chief Strategy Officer	4.8yrs	Nessun dato	Nessun dato
Christina Siniscalchi	Chief Quality Officer	less than a year	Nessun dato	Nessun dato
Anthony Maffia	Chief Regulatory Affairs Officer	less than a year	Nessun dato	Nessun dato

1.8yrs

Durata media

48yo

Età media

Gestione esperta: Il team dirigenziale di ALVO non è considerato esperto (durata media 1.8 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Robert Wessman	CEO, Founder & Executive Chairman	5.8yrs	US$1.52m	Nessun dato
Faysal Kalmoua	COO & Director	4.3yrs	Nessun dato	0% ISK 0
Hjorleifur Palsson	Director	no data	Nessun dato	Nessun dato
Linda McGoldrick	Independent Non-Executive Director	2.3yrs	US$81.00k	0.0035% ISK 18.8m
Lisa Graver	Non-Executive Director	2.3yrs	US$71.00k	0.0035% ISK 18.8m
Tomas Ekman	Non-Executive Director	5.8yrs	Nessun dato	Nessun dato
Arni Hardarson	Non-Executive Director	2.3yrs	Nessun dato	Nessun dato
Richard Davies	Independent Non-Executive Deputy Chairman	5.8yrs	US$156.00k	0.35% ISK 1.9b
Ann Merchant	Independent Non-Executive Director	2.3yrs	US$113.00k	0.0035% ISK 18.8m

3.3yrs

Durata media

57yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ALVO sono considerati esperti (durata media dell'incarico 3.3 anni).

Alvotech Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Alvotech Appoints Hjörleifur Pálsson as Director

Alvotech, Annual General Meeting, Jun 07, 2024

Alvotech Announces Executive Changes

Alvotech Announces Changes to the Leadership Team

Alvotech, Annual General Meeting, Jun 06, 2023

Alvotech Announces Executive Changes, Effective January 1, 2023

Recent updates

Alvotech and Teva Pharmaceutical Industries Ltd. Announce U.S. FDA Approval of Additional Presentation of SELARSDI (ustekinumab-aekn)

Alvotech Announces European Medicines Agency Confirms Acceptance of Marketing Application for AVT03, Proposed Biosimilar to Prolia and Xgeva

Alvotech Initiates Confirmatory Patient Study for AVT16

Forecast breakeven date pushed back to 2026

Second quarter 2024 earnings released: EPS: US$0.25 (vs US$0.83 in 2Q 2023)

Alvotech announces the European Medicines Agency Accepts a Marketing Authorization Application for AVT06, Alvotech’s Proposed Biosimilar to Eylea® (aflibercept)

STADA and Alvotech Launch Uzpruvo

Alvotech Announces Positive Topline Results from Confirmatory Patient Study for Avt03, A Proposed Biosimilar for Prolia® and Xgeva®

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech has filed a Follow-on Equity Offering in the amount of $75 million.

Alvotech Appoints Hjörleifur Pálsson as Director

First quarter 2024 earnings released: US$0.89 loss per share (vs US$1.24 loss in 1Q 2023)

Alvotech, Annual General Meeting, Jun 07, 2024

Alvotech Announces Topline Results from A Confirmatory Clinical Study for AVT05, A Proposed Biosimilar for Simponi (Golimumab)

Alvotech and Teva Announces U.S. FDA Approval of SELARSDI (ustekinumab-aekn), biosimilar to Stelara (ustekinumab)

Forecast to breakeven in 2025

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$2.43 loss per share (vs US$2.60 loss in FY 2022)

Alvotech Announces Executive Changes

Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia and Xgeva

Alvotech Provides Update on Status of Biologics License Applications for Avt02 and Avt04

STADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara

Alvotech Announces Positive Top-Line Results from A Pharmacokinetic Study for Avt05

Third quarter 2023 earnings released: US$0.81 loss per share (vs US$0.04 loss in 3Q 2022)

Light Curve Capital Holdings Pte. Ltd made an offer to acquire Alvotech Hannover Gmbh from Alvotech (NasdaqGM:ALVO).

STADA and Alvotech Receive Positive CHMP Opinion for Europe's First Ustekinumab Biosimilar to Stelara

Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04

Alvotech Announces Approval in Japan of Avt04 (Ustekinumab), A Biosimilar to Stelara®

Alvotech Announces U.S. Food and Drug Administration Accepts its Resubmitted Biologics License Application (BLA) for AVT02

Alvotech Announces Changes to the Leadership Team

Forecast breakeven date pushed back to 2025

Second quarter 2023 earnings released: EPS: US$0.85 (vs US$0.58 loss in 2Q 2022)

Alvotech and Bioventure Announces Approval of AVT02 (Adalimumab) in Egypt

Alvotech announced that it expects to receive $40 million in funding from Teva Pharmaceutical Industries Limited

Alvotech to Report Q3, 2023 Results on Nov 14, 2023

Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02

Forecast breakeven date moved forward to 2024

First quarter 2023 earnings released: US$1.24 loss per share (vs US$0.51 loss in 1Q 2022)

Alvotech, Annual General Meeting, Jun 06, 2023

Alvotech Initiates Confirmatory Patient Study for AVT05, Proposed Biosimilar for Simponi and Simponi Aria

Alvotech to Report Q1, 2023 Results on May 18, 2023

Forecast breakeven date pushed back to 2025

Full year 2022 earnings released: US$2.60 loss per share (vs US$0.92 loss in FY 2021)

European Medicines Agency Accepts a Marketing Authorization Application for AVT04 of Alvotech

Alvotech Announces European Medicines Agency (EMA) Accepts Marketing Authorization Application for AVT04

Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia

Alvotech Initiates Pharmacokinetic Study for AVT05

Alvotech and Teva Announces Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)

Alvotech Announces FDA Grant A New Biosimilar User Fee Amendment

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Alvotech Announces Executive Changes, Effective January 1, 2023

Alvotech announced that it has received $50 million in funding from Alvogen, Inc.

Third quarter 2022 earnings released

Alvotech announced that it has received $50 million in funding from Alvogen, Inc.

Less than half of directors are independent

Alvotech Announces Australian Marketing Authorization for AVT02, A Biosimilar to Humira

Alvotech to Report Nine Months, 2022 Results on Nov 15, 2022

Alvotech Announces Executive Changes

Alvotech and STADA Increase Access to Adalimumab for Patients in Switzerland with the Launch of Hukyndra®

Alvotech Reports Update on Initial AVT02 Biologics License Application

Alvotech Reports Update on Initial AVT02 Biologics License Application

Alvotech Initiates Confirmatory Patient Study for Avt03, A Proposed Biosimilar for Prolia® and Xgeva®

Alvotech to Report Q2, 2022 Results on Aug 31, 2022

Alvotech Initiates Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

Alvotech Expands its Board of Directors as Part of Transition from Private to Publicly Traded Company

Alvotech Initiates Patient Study for AVT06

No independent directors

Analisi delle retribuzioni degli amministratori delegati